Autolus Therapeutics plc filed a Form 8-K on August 3, 2026, announcing an increase to its full-year 2026 net product Revenue guidance for AUCATZYL, anticipated Q2 2026 revenue figures, gross Margin expectations, a new Credit Facility , and an updated cash runway outlook.

Key Highlights

  • Raised guidance: Full-year 2026 AUCATZYL net product revenue guidance increased to $140 million to $150 million, up from the prior range of $120 million to $135 million.
  • Cash runway: The company expects cash, cash equivalents, and marketable securities to fund operations into the second quarter of 2028.
  • New credit facility: The filing references proceeds from a new credit facility as part of the current operating plan supporting the cash runway outlook.
  • Additional updates: The press release also addressed anticipated Q2 2026 AUCATZYL net product revenue and gross margin percentage on AUCATZYL sales during the first half of 2026.
  • Signed by CEO: The report was signed by Christian Itin, Ph.D., Chief Executive Officer, dated August 3, 2026.

Autolus Updates AUCATZYL Revenue Outlook and Cash Position for 2026

According to the filing, Autolus Therapeutics plc ( Nasdaq : AUTL), incorporated in England and Wales, issued a press release on August 3, 2026, covering several financial updates related to its approved product AUCATZYL (obe-cel; obecabtagene autoleucel). The company disclosed an upward revision to its 2026 full-year net product revenue guidance for AUCATZYL, raising the range to $140 million to $150 million from the prior guidance of $120 million to $135 million.

The filing also stated that the press release included the company's anticipated Q2 2026 net product revenue from AUCATZYL and its anticipated gross margin percentage on AUCATZYL sales during the first half of 2026, though specific figures for these items were not reproduced within the 8-K body itself and are contained in Exhibit 99.1. The company reported entering a new credit facility, with proceeds from that facility incorporated into its current operating plans alongside anticipated AUCATZYL revenues.

Based on those combined factors, the company disclosed that it expects its "current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company's operations into the second quarter of 2028." The filing notes that statements regarding anticipated revenues, cash runway, and other matters are forward-looking statements subject to risks and uncertainties identified in the company's Annual Report on Form 10-K filed with the SEC on March 27, 2026, and subsequent filings. The company stated it undertakes no obligation to update forward-looking statements except as required by law.

What Was Disclosed

Autolus Therapeutics disclosed an increase in its 2026 AUCATZYL net product revenue guidance to $140 million to $150 million, a new credit facility, and an extended cash runway expected to reach into Q2 2028, as reported in its August 3, 2026 Form 8-K.